PROTAGONIST THERAPEUTICS INC

Protagonist Therapeutics’ peptide‑based biotech breakthrough sparks investor optimism, yet a 119x P/E ratio raises questions about future returns.

FDA approves Protagonist’s MIMRYLO, the first peptide therapy for polycythemia vera, cutting phlebotomy use and boosting patient energy.

Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company with innovative peptide-based therapies, but its high price-to-earnings ratio and industry risks raise questions about its sustainability and true value.

Protagonist Therapeutics, a clinical-stage biopharmaceutical company, has seen notable stock performance, with a market capitalization of $3.34 billion and a price-to-earnings ratio of 71.08.